NCT07352176

Brief Summary

Forty subjects meeting the inclusion and exclusion criteria were recruited at a single center and signed informed consent forms. Among them, 20 patients in the diffuse group and 20 patients in the localized group were randomly assigned to the conventional radial endobronchial ultrasound combined with cryobiopsy group (conventional group) and the confocal laser endomicroscopy combined with cryobiopsy group (combined group). During the operation, the operator manipulated the bronchoscope to reach the lesion. After confirming the arrival at the lesion using radial endobronchial ultrasound/confocal laser endomicroscopy, cryobiopsy was performed, and the size of the sample was recorded. CBCT scanning was conducted after cryobiopsy. If there was no hole-in-lesion image, cryobiopsy was performed again under CBCT guidance. CBCT scanning was performed after biopsy to determine whether there were any adverse events.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
8mo left

Started Feb 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress29%
Feb 2026Dec 2026

First Submitted

Initial submission to the registry

January 11, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 20, 2026

Completed
12 days until next milestone

Study Start

First participant enrolled

February 1, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

January 20, 2026

Status Verified

January 1, 2026

Enrollment Period

11 months

First QC Date

January 11, 2026

Last Update Submit

January 11, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Incidence of adverse events

    The Incidence of adverse events = (the number of adverse event / the number of procedures) \* 100%

    7 days after procedure

Secondary Outcomes (2)

  • Diagnostic yield

    Immediately after the procedure

  • Hole-in-lesion rate

    During the procedure

Study Arms (4)

Diffuse- Conventional Group

ACTIVE COMPARATOR

The Diffuse-Conventional Group used conventional cryobiopsy for lung lesions.

Other: Conventional cryobiopsy

Diffuse- Combined Group

EXPERIMENTAL

The Diffuse-Combined Group used CLE combined with cryobiopsy for lung lesions

Other: Confocal laser endomicroscopy combined cryobiopsy

Localized - Convention Group

ACTIVE COMPARATOR

The Localized-Conventional Group used conventional cryobiopsy for lung lesions.

Other: Conventional cryobiopsy

Localized - Combined Group

EXPERIMENTAL

The Localized-Combined Group used CLE combined with cryobiopsy for lung lesions

Other: Confocal laser endomicroscopy combined cryobiopsy

Interventions

Patients in the conventional group will underg cryobiopsy for lung lesions.

Diffuse- Conventional GroupLocalized - Convention Group

Patients in the combined group will undergo CLT combined with cryobiopsy for lung lesions.

Diffuse- Combined GroupLocalized - Combined Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients over 18 years old with lung lesions indicated by chest CT;
  • Preoperative CT indicates that the lung lesion to be biopsied has a bronchus leading to it;
  • Able to understand and voluntarily sign the written informed consent form. -

You may not qualify if:

  • Patients with contraindications to anesthesia or bronchoscopy;
  • Patients with uncorrectable coagulation disorders;
  • Patients who cannot discontinue therapeutic anticoagulants within an appropriate time interval before surgery;
  • Patients with severe liver or kidney dysfunction, mental illness, etc.;
  • Pregnant or lactating patients;
  • Patients without a clear histological or clinical diagnosis;
  • Subjects deemed unsuitable for participation in this study by the investigator.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510163

Guangzhou, Guangdong, 510100, China

Location

Related Publications (3)

  • Kramer T, Wijmans L, de Bruin M, van Leeuwen T, Radonic T, Bonta P, Annema JT. Bronchoscopic needle-based confocal laser endomicroscopy (nCLE) as a real-time detection tool for peripheral lung cancer. Thorax. 2022 Apr;77(4):370-377. doi: 10.1136/thoraxjnl-2021-216885. Epub 2021 Jun 25.

    PMID: 34172559BACKGROUND
  • Wellikoff AS, Holladay RC, Downie GH, Chaudoir CS, Brandi L, Turbat-Herrera EA. Comparison of in vivo probe-based confocal laser endomicroscopy with histopathology in lung cancer: A move toward optical biopsy. Respirology. 2015 Aug;20(6):967-74. doi: 10.1111/resp.12578. Epub 2015 Jun 19.

    PMID: 26094505BACKGROUND
  • Sorokina A, Danilevskaya O, Averyanov A, Zabozlaev F, Sazonov D, Yarmus L, Lee HJ. Comparative study of ex vivo probe-based confocal laser endomicroscopy and light microscopy in lung cancer diagnostics. Respirology. 2014 Aug;19(6):907-13. doi: 10.1111/resp.12326. Epub 2014 Jun 9.

    PMID: 24909555BACKGROUND

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

January 11, 2026

First Posted

January 20, 2026

Study Start

February 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

January 20, 2026

Record last verified: 2026-01

Locations